Stay Ahead of Compliance with Monthly Citation Updates


In your State Survey window and need a snapshot of your risks?

Survey Preparedness Report

One Time Fee
$79
  • Last 12 months of citation data in one tailored report
  • Pinpoint the tags driving penalties in facilities like yours
  • Jump to regulations and pathways used by surveyors
  • Access to your report within 2 hours of purchase
  • Easily share it with your team - no registration needed
Get Your Report Now →

Monthly citation updates straight to your inbox for ongoing preparation?

Monthly Citation Reports

$18.90 per month
  • Latest citation updates delivered monthly to your email
  • Citations organized by compliance areas
  • Shared automatically with your team, by area
  • Customizable for your state(s) of interest
  • Direct links to CMS documentation relevant parts
Learn more →

Save Hours of Work with AI-Powered Plan of Correction Writer


One-Time Fee

$49 per Plan of Correction
Volume discounts available – save up to 20%
  • Quickly search for approved POC from other facilities
  • Instant access
  • Intuitive interface
  • No recurring fees
  • Save hours of work
F0755
D

Pharmacist Failed to Identify and Report Adverse Drug Reactions and Allergy

Martinsburg, West Virginia Survey Completed on 06-25-2025

Penalty

No penalty information released
tooltip icon
The penalty, as released by CMS, applies to the entire inspection this citation is part of, covering all citations and f-tags issued, not just this specific f-tag. For the complete original report, please refer to the 'Details' section.

Summary

The consulting pharmacist failed to identify and notify the physician of potential adverse drug reactions (ADRs) related to the concurrent administration of opioids and benzodiazepines for a female resident with multiple complex diagnoses, including acute and chronic respiratory failure, paroxysmal atrial fibrillation, COPD, Alzheimer's disease, major depressive disorder, and atherosclerotic heart disease. The resident, who had a BIMS score of 2 indicating severely impaired cognition, was prescribed lorazepam (a benzodiazepine) as needed for anxiety and tramadol (an opioid) daily, despite a documented allergy to tramadol (hallucinations). The resident was frequently observed asleep throughout the survey period, with little documentation regarding her sleep patterns or quality of life. Record review showed no evidence that the pharmacist identified or communicated the risks of concurrent use of these CNS depressants, nor was there documentation that the physician was notified about the resident's tramadol allergy. Monthly Monitoring Reports and Gradual Dose Reductions did not address the concurrent use of opioids and benzodiazepines, and there was no documentation that drug-to-drug interactions or possible adverse reactions were considered. Interviews with nursing and pharmacy staff confirmed the lack of physician notification and insufficient documentation regarding the resident's medication regimen and its potential risks.

An unhandled error has occurred. Reload 🗙